Increasing prevalence of various types of soft tissue sarcomas and intensive R&D activities on drugs to drive global soft tissue sarcoma market
According to TechSci Research report, “Global Soft Tissue Sarcoma Market By Treatment (Targeted Therapy, Chemotherapy, Anti-Angiogenesis Drug, Radiation Therapy), By Disease Type (Local Sarcoma, Regional Sarcoma, Metastatic Sarcoma), By End User (Hospitals, Oncology Center, Long Term Care Center), By Region, Forecast & Opportunities, 2025”, the global soft tissue sarcoma market is poised to undergo a robust growth during the forecast period as the world is witnessing increasing cases and prevalence of various types of soft tissue sarcomas. Moreover, growing awareness among people and increasing research & development activities to find the advanced drugs and therapies such as targeted and biological therapies to cure the disease are some key factors propelling the growth of soft tissue sarcoma market. Further, increase in approval for manufacture of generic drugs are expected to fuel the market growth until 2025. Additionally, rising funding and grants by governments for research is providing a major boost to the global soft tissue sarcoma market. Apart from that, rise in quality patient care and patent expiry of branded drugs are other factors driving the growth this market. There are around 50 different types of soft tissue sarcoma and there is a growing need to find a suitable treatment for the ailment. With more manufacturers entering the market, the global soft tissue sarcoma market is anticipated to witness significant growth in the coming years.
However, the market also faces some challenges. High cost and side effects associated with cancer treatment are restraining the growth of global soft tissue sarcoma market. Also, stringent government regulations and shortage of doxorubicin, which is one of the major drugs used in chemotherapy, might act as barriers to the overall growth of this market.
Browse XX market data Tables and XX Figures spread through XXX Pages and an in-depth TOC on “Global Soft Tissue Sarcoma Market”
The global soft tissue sarcoma market is segmented based on treatment, disease type, end user and region. Based on treatment, the market is segmented into targeted therapy, chemotherapy, anti-angiogenesis drug and radiation therapy. Here, the chemotherapy segment accounted for largest market share until 2019 and is expected to dominate the market through 2025 as the treatment uses a combination of various anti-cancer drugs and has high success rate compared to other cancer treatments. Based on end user, the global soft tissue sarcoma market is categorized into hospitals, oncology center, long term care center. As the shortage of oncology centers, especially in developing nations is a major issue, therefore the market is currently being dominated by hospitals. However, with increasing expenditure on healthcare and rise in number of oncology centers, the oncology center segment is expected to undergo fastest growth during the forecast period.
Major players operating in the global soft tissue sarcoma market include GlaxoSmithKline plc, Eli Lilly and Company, Pfizer, Inc., Bristol-Myers Squibb, F. Hoffmann-La Roche AG, Johnson & Johnson Services, Inc., Teva Pharmaceutical Industries Ltd, Celgene Corporation, BioHorizons, Zimmer Holdings, RTI Biologics, MiMedx, Atrium Medical and Integra LifeSciences. The companies are focusing on new product launches and research & development activities to bring more effective treatments and drugs for soft tissue sarcoma.
Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=4840
Customers can also request for 10% free customization on this report.
“North America is emerging as the biggest market for soft tissue sarcoma as the region has a large population suffering from chronic diseases such as cancer. The advanced healthcare facilities and rising awareness about soft tissue sarcoma are making the region one of the most favorable markets for the manufacturers. The region is expected to be followed by Europe and Asia-Pacific, which are also witnessing rising cases of soft tissue sarcoma ,” said Mr. Karan Chechi, Research Director with TechSci Research, a research based global management consulting firm.
“Global Soft Tissue Sarcoma Market By Treatment (Targeted Therapy, Chemotherapy, Anti-Angiogenesis Drug, Radiation Therapy), By Disease Type (Local Sarcoma, Regional Sarcoma, Metastatic Sarcoma), By End User (Hospitals, Oncology Center, Long Term Care Center), By Region, Forecast & Opportunities, 2025”has evaluated the future growth potential of global soft tissue sarcoma market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges and opportunities in global soft tissue sarcoma market.
Mr. Ken Mathews
708 Third Avenue,
New York – 10017